Cyxone in strategic development co-operation with European CRO

Cyxone can announce today that it has established a long-term strategic co-operation agreement with Sourcia, a clinical contract research organization (CRO) with offices in Belgium, Germany, and the Netherlands.

Cyxone's business model is to establish co-operation with different partners, and limited numbers of its own staff, to conduct studies flexibly and cost effectively. We have previously reported on our studies with T20K carried out by companies in Australia, Austria, Denmark, Germany, Sweden, Switzerland, and the US.

To efficiently take T20K through the pre-clinical studies and studies in humans, Cyxone needs long-term strategic co-operation with a CRO that offers the various competences and services that the company needs over time, without having to establish costly infrastructure.

In Q4 2016, Cyxone evaluated a number of CRO's in Europe and North America, and in Q1 2017 actively worked with Sourcia's team of experts to formulate T20K's development plan for Multiple Sclerosis.

Following this test period, the company now feels confident about long-term co-operation with Sourcia to conduct its pre-clinical and clinical development programme.

Through its co-operation with Sourcia, Cyxone considerably increases its strategic capacity to successfully move T20K forward through pre-clinical and clinical development.

May 18, 2017

For more information, please contact: 
Cyxone AB (publ.)
Kjell G. Stenberg, CEO
Tel: +46 (0) 723 816 168
Email: kjell.g.stenberg@cyxone.com
Adelgatan 21
211 22 Malmö
cyxone.com

This information is information which Cyxone AB (publ) is obliged to publish under the EU Market Abuse Regulation. The information was provided by the auspices of the above contact person, for publication on May 18, 2017.

About Cyxone 
Cyxone AB (publ.) is a biopharmaceutical company that develops drugs based on cyclotides, a class of natural plant protein. Cyclotide technology has the potential to provide new drugs with beneficial pharmacological effects on diseases that currently lack safe and effective treatments. The company is focusing on the development of T20K, a substance that inhibits key processes in cells that are typically associated with various immune disorders, such as multiple sclerosis and rheumatoid arthritis. Cyxone's Certified Adviser on the Nasdaq First North is Erik Penser Bank.